Rejuveinix (RJX) / Reven Holdings 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rejuveinix (RJX) / Reven Holdings
RJX, NCT04708340: Tolerability and Efficacy of in Patients With COVID-19

Active, not recruiting
1/2
237
US
Rejuveinix (RJX) Active Comparator, RJX, Rejuveinix, Placebo Comparator, 0.9% Sodium Chloride in Water for Injection, USP., Normal Saline for Injection, USP
Reven Pharmaceuticals, Inc.
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
10/22
02/23

Download Options